Aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder
Conditions
Interventions
Observation group:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients meeting the 2015 International Panel for NMO Diagnosis (IPND) criteria for NMOSD; 2.Seropositive for AQP4-IgG, detected by cell-based assay (CBA) or other methods validated by the investigators as reliable; 3.Received >=1 dose of satralizumab (SAT), inebilizumab (INE), or mycophenolate mofetil (MMF); 4.Have verifiable diagnostic and treatment records; 5.Completed at least one follow-up visit after treatment initiation; 6.Possess relatively complete clinical data required for the study; 7.Identifiable within the national health insurance reimbursement database;
Exclusion criteria
Exclusion criteria: 1.Patients with severe organ dysfunction or concomitant active autoimmune diseases; 2.Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) seropositivity; 3.Significant missing data in key clinical or cost variables; 4.Treatment switching during follow-up (to be addressed via sensitivity analysis or censoring);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to first protocol-defined relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| annualized relapse rate; | — |
Countries
China
Contacts
Public ContactYan Xu
Peking Union Medical College Hospital
Outcome results
None listed